{"groups":[{"description":"Weeks 1 and 3: CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: CRS-207\n\nMaintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy plus chemotherapy: live attenuated double deleted Lm","id":"FG000","title":"Immunotherapy Plus Chemotherapy"},{"description":"Weeks 1 and 3: cyclophosphamide (200 mg/m\\^2), CRS-207 (1 × 10\\^9 CFU)\n\nWeeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m\\^2) and cisplatin (75 mg/m\\^2)\n\nWeeks 23 and 26: cyclophosphamide one day before CRS-207\n\nMaintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression\n\nImmunotherapy with cyclophosphamide plus chemotherapy: live attenuated double deleted Lm","id":"FG001","title":"Immunotherapy With Cyclophosphamide Plus Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Clinical progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"22"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}